UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Author Correction: Differentiating central nervous system infection from disease infiltration in hematological malignancy

Scientific reports, 2022-12, Vol.12 (1), p.21009-21009, Article 21009

2022

Volltextzugriff (PDF)

Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party

Bone marrow transplantation (Basingstoke), 2019-10, Vol.54 (10), p.1625-1631

2019

Volltextzugriff (PDF)

Management of primary and secondary CNS lymphoma

Hematological oncology, 2023-06, Vol.41 (S1), p.25-35

2023

Volltextzugriff (PDF)

EXABS-231-ABCL The Treatment of Primary and Secondary CNS Lymphoma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S119-S122

2023

Volltextzugriff (PDF)

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up

HemaSphere, 2024-06, Vol.8 (6), p.e89-n/a

2024

Volltextzugriff (PDF)

Evidence-based management of primary and secondary CNS lymphoma

Seminars in hematology, 2023-11, Vol.60 (5), p.313-321

2023

Volltextzugriff (PDF)

S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559)

HemaSphere, 2023-08, Vol.7 (S3), p.e2454568-n/a

2023

Volltextzugriff (PDF)

P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

HemaSphere, 2022-10, Vol.6 (Suppl), p.7-8

2022

Volltextzugriff (PDF)

Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma

Current opinion in oncology, 2023-09, Vol.35 (5), p.382-388

2023

Volltextzugriff (PDF)

230 A dog with a bone (marrow biopsy)

Journal of neurology, neurosurgery and psychiatry, 2019-12, Vol.90 (12), p.e58-e58

2019

Volltextzugriff (PDF)

Extending potentially curative options for older patients with PCNSL

The Lancet. Haematology, 2024-03, Vol.11 (3), p.e171-e173

2024

Volltextzugriff (PDF)

Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice Paper

British journal of haematology, 2024-08

2024

Volltextzugriff (PDF)

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

The New England journal of medicine, 2024-01, Vol.390 (4), p.326-337

2024

Volltextzugriff (PDF)

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.10316-10317

2022

Volltextzugriff (PDF)

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.302-302

2023

Volltextzugriff (PDF)

Peripheral T-cell lymphoma with bilateral ocular involvement

Indian journal of ophthalmology - case reports, 2024-04, Vol.4 (2), p.348-351

2024

Volltextzugriff (PDF)

Impact of Double Expression of MYC and BCL-2 on Outcomes in Primary CNS Lymphoma: A UK Multicentre Analysis

Blood, 2022-11, Vol.140 (Supplement 1), p.372-374

2022

Volltextzugriff (PDF)

Interpretation of retrospective data evaluating high‐dose methotrexate as central nervous system prophylaxis in diffuse large B‐cell lymphoma; caution required

American journal of hematology, 2021-09, Vol.96 (9), p.E338-E339

2021

Volltextzugriff (PDF)

Steroid Use, Advanced Stage Disease and ≥3 Lines of Prior Chemotherapy Are Associated with a Higher Risk of Infection Following CD19 CAR T-Cell Therapy for B-NHL: Real World Data from a Large UK Center

Blood, 2020-11, Vol.136 (Supplement 1), p.20-21

2020

Volltextzugriff (PDF)

AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

Blood, 2020-11, Vol.136 (Supplement 1), p.18-19

2020

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

KollektionTaylor & Francis:Master (3349 titles)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(80)

Publikationsform

Sprache

Englisch
(89)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience

Author Correction: Differentiating central nervous system infection from disease infiltration in hematological malignancy

Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party

Management of primary and secondary CNS lymphoma

EXABS-231-ABCL The Treatment of Primary and Secondary CNS Lymphoma

Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up

Evidence-based management of primary and secondary CNS lymphoma

S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559)

P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma

230 A dog with a bone (marrow biopsy)

Extending potentially curative options for older patients with PCNSL

Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice Paper

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Peripheral T-cell lymphoma with bilateral ocular involvement

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Impact of Double Expression of MYC and BCL-2 on Outcomes in Primary CNS Lymphoma: A UK Multicentre Analysis

Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Interpretation of retrospective data evaluating high‐dose methotrexate as central nervous system prophylaxis in diffuse large B‐cell lymphoma; caution required

Steroid Use, Advanced Stage Disease and ≥3 Lines of Prior Chemotherapy Are Associated with a Higher Risk of Infection Following CD19 CAR T-Cell Therapy for B-NHL: Real World Data from a Large UK Center

AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

Aktive Filter

Suchergebnisse filtern